Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × tucatinib × 90 days × Clear all

Phase

Phase 2 11 Phase 3 2 Phase 1/2 2 Phase 1 2 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Cisplatin 18 Magnetic Resonance Spectroscopy 16 Carboplatin 15 pembrolizumab 12 Specimen Handling 12 Gemcitabine 10 Doxorubicin 10 Paclitaxel 9 Pemetrexed 8 Nivolumab 8 Cyclophosphamide 8 atezolizumab 7 Radiotherapy 7 Radiation 7 Docetaxel 7 Platinum 6 Oxaliplatin 6 Biopsy 6 Bevacizumab 6 130-nm albumin-bound paclitaxel 6 1,2-diaminocyclohexaneplatinum II citrate 6 Ipilimumab 5 Immunoglobulin G 5 Drug Therapy 5 Disulfides 5 Capecitabine 5 venetoclax 4 Vincristine 4 Trastuzumab 4 Temozolomide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡